News | Image Guided Radiation Therapy (IGRT) | June 19, 2017

Henry Ford Cancer Institute First in World to Install Viewray MRIdian Linac

MRI-guided radiation therapy system combines real-time tumor assessment with linear accelerator delivery

Henry Ford Cancer Institute First in World to Install Viewray MRIdian Linac

June 19, 2017 — The Henry Ford Cancer Institute is the first in Michigan – and first in the world – to offer patients advanced radiation therapy with the ViewRay MRIdian Linac system. The system uses a U.S. Food and Drug Administration (FDA)-approved real-time magnetic resonance imaging (MRI) and linear accelerator delivery for more precise and accurate radiation treatment.

The ViewRay MRIdian Linac is the world's first and only FDA-approved commercially available linear accelerator-based MRI-guided radiation therapy system that can image and treat patients simultaneously, according to Viewray. The FDA approved the company's next-generation model for use in February.

The same model is being installed at the Cancer Institute at Henry Ford Medical Center-Cottage in Grosse Pointe Farms. It will be ready for treating patients in July 2017.

Benjamin Movsas, M.D., chair of the Department of Radiation Oncology at the Cancer Institute and a national expert, said the system offers "game-changing technology" in radiation therapy.

"This is the future in our field," Movsas said. "This technology will allow us to optimize in real-time the delivery of radiation."

Movsas said while the system will be used to treat all types of cancers anywhere in the body, it is especially beneficial for tumors where there is typically movement during treatment, including tumors in the liver, pancreas, adrenal and lung. Other types of cancer this advanced system will deliver a new level of care to include breast, prostate, kidney and gynecologic cancers, among others.

Indrin Chetty, Ph.D., division head of Physics in Radiation Oncology, said the MRIdian Linac system further enhances radiation therapy with:

  • Personalized treatment. By continuously observing and assessing the patient's tumor and internal organs, clinicians can tailor treatment to each individual;
  • Precision and accuracy. High-quality images and continuous soft-tissue imaging are provided while the radiation beam is on; and
  • Real-time imaging. When clinicians can clearly see the target and watch where the radiation is being delivered, they are better able to adapt to changes in the patient's anatomy.

Over the years, technology has improved the accuracy of radiation treatment while protecting surrounding healthy tissue. However, trying to accommodate for the natural movement of a tumor and the body's internal organs during treatment has been elusive.

The ViewRay system combines the effectiveness of MRI, which produces high-quality images of organs and structures inside the body, with a linear accelerator to map out a therapy plan and deliver radiation at the intended target, while allowing for refinements to be made in real-time during treatment. The result is a more accurate, precise treatment.

For more information: www.viewray.com

Related Content

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories
News | Patient Positioning Radiation Therapy | July 19, 2019
A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
CMS Proposes New Alternative Payment Model for Radiation Oncology
News | Radiation Oncology | July 17, 2019
The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
RaySearch Releases Version 3A of RayCare Oncology Information System
Technology | Oncology Information Management Systems (OIMS) | July 15, 2019
RaySearch has released RayCare 3A, a new version of the next-generation oncology information system (OIS). RayCare is...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
IBA Launches Monte Carlo Patient QA for Varian Halcyon at AAPM 2019
Technology | Quality Assurance (QA) | July 10, 2019
IBA announced the launch of the latest functionality of the SciMoCa Monte Carlo Patient QA solution at the 61st annual...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...